MX2022012407A - Composiciones de virus adenoasociados para la transferencia del gen ids y sus metodos de uso. - Google Patents

Composiciones de virus adenoasociados para la transferencia del gen ids y sus metodos de uso.

Info

Publication number
MX2022012407A
MX2022012407A MX2022012407A MX2022012407A MX2022012407A MX 2022012407 A MX2022012407 A MX 2022012407A MX 2022012407 A MX2022012407 A MX 2022012407A MX 2022012407 A MX2022012407 A MX 2022012407A MX 2022012407 A MX2022012407 A MX 2022012407A
Authority
MX
Mexico
Prior art keywords
methods
adeno
associated virus
compositions
gene transfer
Prior art date
Application number
MX2022012407A
Other languages
English (en)
Inventor
Laura Jane Smith
Serena Nicole Dollive
Jacinthe Gingras
Kruti Patel
Yvonne White
Lieshout Laura Van
Brenda Burnham
Original Assignee
Homology Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Homology Medicines Inc filed Critical Homology Medicines Inc
Publication of MX2022012407A publication Critical patent/MX2022012407A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A01K2217/077—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out heterozygous knock out animals displaying phenotype
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan composiciones de virus adenoasociados (AAV) que pueden restaurar la función del gen IDS en las células, y métodos para usar estas composiciones de AAV para tratar trastornos asociados con la reducción de la función del gen IDS (por ejemplo, síndrome de Hunter). También se proporcionan composiciones, sistemas y métodos para preparar las composiciones de AAV.
MX2022012407A 2020-04-06 2021-04-05 Composiciones de virus adenoasociados para la transferencia del gen ids y sus metodos de uso. MX2022012407A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063005833P 2020-04-06 2020-04-06
US202063094800P 2020-10-21 2020-10-21
US202163145258P 2021-02-03 2021-02-03
PCT/US2021/025785 WO2021207077A1 (en) 2020-04-06 2021-04-05 Adeno-associated virus compositions for ids gene transfer and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022012407A true MX2022012407A (es) 2022-10-28

Family

ID=78022877

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012407A MX2022012407A (es) 2020-04-06 2021-04-05 Composiciones de virus adenoasociados para la transferencia del gen ids y sus metodos de uso.

Country Status (13)

Country Link
US (1) US20210361778A1 (es)
EP (1) EP4132562A4 (es)
JP (1) JP2023522852A (es)
KR (1) KR20220164743A (es)
CN (1) CN115484975A (es)
AU (1) AU2021252515A1 (es)
BR (1) BR112022019182A2 (es)
CA (1) CA3173207A1 (es)
CO (1) CO2022013833A2 (es)
IL (1) IL296986A (es)
MX (1) MX2022012407A (es)
TW (1) TW202204629A (es)
WO (1) WO2021207077A1 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326327C (en) * 1998-04-24 2009-06-16 University Of Florida Recombinant adeno-associated virus vector encoding alpha-1-antitrypsin serum protein
US7985553B2 (en) * 2001-10-29 2011-07-26 Nathaniel Heintz Method for isolating cell type-specific mRNAs
EP2325301B1 (en) * 2003-02-11 2015-09-02 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
US8628966B2 (en) * 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
US20180127733A9 (en) * 2010-11-12 2018-05-10 Green Cross Corporation Iduronate-2-sulfatase and use thereof
EP2833892A4 (en) * 2012-04-02 2016-07-20 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
EP3097197B1 (en) * 2014-01-21 2020-12-16 Vrije Universiteit Brussel Muscle-specific nucleic acid regulatory elements and methods and use thereof
ES2821149T3 (es) * 2014-03-12 2021-04-23 Prec Biosciences Inc Eliminación del exón del gen de la distrofina mediante nucleasas modificadas genéticamente
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
KR20230125339A (ko) * 2016-04-15 2023-08-29 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ii형 점액다당류증의 치료를 위한 유전자 요법
CN108977452B (zh) * 2017-05-31 2022-07-19 北卡罗来纳大学教堂山分校 优化的人凝血因子ix基因表达盒及其应用
BR112020007765A2 (pt) * 2017-10-18 2020-10-20 City Of Hope composições de vírus adeno-associados para restaurar a função do gene hbb e métodos de uso das mesmas
CN111902164A (zh) * 2018-02-01 2020-11-06 同源药物公司 用于恢复pah基因功能的腺相关病毒组合物及其使用方法
KR20220112283A (ko) * 2019-12-10 2022-08-10 다케다 야쿠힌 고교 가부시키가이샤 Hunter 질환 치료용 아데노-연합된 바이러스 벡터

Also Published As

Publication number Publication date
WO2021207077A1 (en) 2021-10-14
IL296986A (en) 2022-12-01
CA3173207A1 (en) 2021-10-14
CO2022013833A2 (es) 2022-10-31
KR20220164743A (ko) 2022-12-13
BR112022019182A2 (pt) 2022-11-29
EP4132562A1 (en) 2023-02-15
TW202204629A (zh) 2022-02-01
JP2023522852A (ja) 2023-06-01
US20210361778A1 (en) 2021-11-25
AU2021252515A1 (en) 2022-10-27
CN115484975A (zh) 2022-12-16
EP4132562A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
NZ596022A (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
BR112017015845A2 (pt) anticorpo, métodos para neutralizar ebov infeccioso, para prevenir, tratar ou melhorar pelo menos um sintoma de infeção por ebov ou diminuir a frequência ou gravidade de pelo menos um sintoma de infeção por ebov e para aumentar a sobrevivência ou a probabilidade de sobrevivência de um indivíduo que sofre de infeção com ebov ou um indivíduo exposto ao ebov ou em risco de exposição ou aquisição do ebov, composição farmacêutica, molécula polinucleotídica isolada, vetor, e, célula.
MX2019013151A (es) Composiciones y metodos para expresar otoferlina.
NO20054343L (no) Behandling av immunologiske lidelser ved anvendelse av agonister av interleukin-21/interleukin-21 reseptor
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2020005282A (es) Vector para la produccion de particulas aav.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2021014525A (es) Adenovirus modificados.
WO2020219988A3 (en) Engineering aav
BR112019022901A2 (pt) precursor de linhagem mesenquimal ou células t com imunossupressão intensificada
MX2019003191A (es) Microorganismos oxidantes de amoníaco para uso y suministro al sistema intranasal.
AR116569A1 (es) Terapia génica para tratar la acidemia propiónica
EA202091844A1 (ru) Композиции аденоассоциированных вирусов для переноса гена pah и способы их применения
PH12020551573A1 (en) Pharmaceutical compositions for inhibiting inflammatory cytokines
WO2021222476A3 (en) High efficiency gene delivery system
PH12021550103A1 (en) Low endotoxin fucan compositions, systems and methods
CA3076277A1 (en) Method for treating cancer with a coxsackievirus b3 (cvb3) variant
MX2022004352A (es) Vectores virales adenoasociados para el tratamiento de la enfermedad de niemann-pick tipo c.
BR112021024855A2 (pt) Composições de vírus adenoassociados para transferência de gene arsa e métodos de uso das mesmas
MX2020008133A (es) Composiciones de virus adeno-asociado para restaurar la funcion del gen pah y metodos de uso de las mismas.
MX2022012407A (es) Composiciones de virus adenoasociados para la transferencia del gen ids y sus metodos de uso.
MX2022014881A (es) Composiciones de virus adenoasociados para restaurar la funcion del gen pah y metodos de uso de las mismas.
MX2022005670A (es) Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn.